BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 24037430)

  • 1. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
    Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
    Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic status determines
    Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
    Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
    Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up.
    Lepoutre-Lussey C; Caramella C; Bidault F; Déandreis D; Berdelou A; Al Ghuzlan A; Hartl D; Borget I; Gimenez-Roqueplo AP; Dumont F; Deschamps F; Nascimento C; Lumbroso J; Guillaud Bataille M; Schlumberger M; Baudin E; Leboulleux S
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):868-76. PubMed ID: 25676472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
    Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
    J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery.
    Nockel P; El Lakis M; Gaitanidis A; Merkel R; Patel D; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Ann Surg; 2019 Apr; 269(4):741-747. PubMed ID: 29334561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (11)C-hydroxyephedrine positron emission tomography in the postoperative management of pheochromocytoma and paraganglioma.
    Yamamoto S; Wassberg C; Hellman P; Sundin A
    Neuroendocrinology; 2014; 100(1):60-70. PubMed ID: 25012453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Subtyping of Pheochromocytoma and Paraganglioma by
    van Berkel A; Vriens D; Visser EP; Janssen MJR; Gotthardt M; Hermus ARMM; Geus-Oei LF; Timmers HJLM
    J Nucl Med; 2019 Jun; 60(6):745-751. PubMed ID: 30413658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pediatric malignant paraganglioma and brief review of the literature.
    Zi J; Ma C; Xu C; Bai Y
    Hell J Nucl Med; 2016; 19(3):281-284. PubMed ID: 27824970
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Jazbec T; Girod PP; Url C; Thomé C; Riechelmann H; Sprinzl GM; Fraedrich G; Virgolini IJ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):94-99. PubMed ID: 30630744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performances of FDG-PET/CT and diffusion-weighted imaging indices for differentiating benign pheochromocytoma from other benign adrenal tumors.
    Nakajo M; Nakajo M; Fukukura Y; Jinguji M; Shindo T; Nakabeppu Y; Kamimura K; Yoneyama T; Takumi K; Yoshiura T
    Abdom Imaging; 2015 Aug; 40(6):1655-65. PubMed ID: 25382022
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kan Y; Zhang S; Wang W; Liu J; Yang J; Wang Z
    Acta Radiol; 2018 Dec; 59(12):1466-1474. PubMed ID: 29566550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
    Taïeb D; Tessonnier L; Sebag F; Niccoli-Sire P; Morange I; Colavolpe C; De Micco C; Barlier A; Palazzo FF; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):580-6. PubMed ID: 18394015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma.
    Puar T; van Berkel A; Gotthardt M; Havekes B; Hermus AR; Lenders JW; van Marken Lichtenbelt WD; Xu Y; Brans B; Timmers HJ
    J Clin Endocrinol Metab; 2016 Jan; 101(1):224-32. PubMed ID: 26574955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.